|
|
Article: Cubicin(R) Granted Marketing Approval in Europe; First-in-Class Antibiotic Approved for Treatment of Complicated Skin and Soft-Tissue Infections; Imminent Product Launch in the UK and the Netherlands.
- Article from:
- Business Wire
- Article date:
- January 23, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EMERYVILLE, Calif. -- Chiron Corporation (Nasdaq:CHIR) today announced that the European Commission has granted marketing approval for CUBICIN(R) (daptomycin), a first-in-class IV antibiotic. The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein and Norway. Under the approval, CUBICIN is indicated for the treatment of complicated skin and soft-tissue infections (cSSTI) caused by Gram-positive bacteria. CUBICIN is expected to become available in the United Kingdom and the Netherlands within the next few weeks, followed by additional European countries, in accordance with local legal regulations.
Gram-positive ...